Fixed-duration venetoclax plus rituximab has shown sustained progression-free survival, overall survival, and minimal residual disease benefits vs bendamustine plus rituximab in patients with relapsed/refractory chronic lymphocytic leukemia, regardless of high-risk biomarkers.
The combination of the humanized anti-GD2 antibody naxitamab-gqgk, irinotecan, temozolomide, and sargramostim met its primary end point for objective response rate in patients with chemoresistant high-risk neuroblastoma.
The rolling biologics license application submission to the FDA to support the approval of omidubicel for patients with blood cancers in need of allogenic hematopoietic stem cell transplant has been completed.
The use of BTK inhibitors as a frontline treatment improved overall survival vs their deployment in subsequent lines of therapy in patients with mantle cell lymphoma, according to a real-world study (IRB-300004501) published in Blood Advances.
The fixed-duration combination of ibrutinib and venetoclax produced deep responses and improved progression-free survival vs chlorambucil plus obinutuzumab when used in previously untreated patients with chronic lymphocytic leukemia who were older and/or who had comorbidities, according to findings from the phase 3 GLOW trial.
For the 10th consecutive year, OncLive® is honored to recognize oncology leaders whose innovations have contributed to immeasurable improvements in outcomes for countless patients.
Press Release
Investigators at the Montefiore Einstein Cancer Center report that Black and Hispanic patients had outcomes and side effects following CAR-T treatment that were comparable to their white and Asian counterparts, according to findings from a study published in Bone Marrow Transplantation.
Second-line treatment with pemigatinib may be linked with prolonged progression-free survival compared with other systemic therapies in patients with cholangiocarcinoma harboring FGFR2 fusions or rearrangements.
The FDA announced that it has withdrawn approval for umbralisib, an oral inhibitor of PI3K-δ and CK1-ε manufactured by TG Therapeutics.
Chung-Han Lee, MD, PhD, explains the historical barriers to treatment developments in non-clear cell renal cell carcinoma; highlights the efficacy of cabozantinib plus nivolumab in patients with unclassified, translocation, papillary, and fumarate hydratase–deficient non-clear cell renal cell carcinoma; and elaborates on the need for increased molecular classification of the histologic subsets of non-clear cell renal cell carcinoma.
Emerging data with novel antibody-drug conjugates such as trastuzumab deruxtecan-nxki, vic-trastuzumab duocarmazine, and disitamab vedotin are showing encouraging activity in HER2-low breast cancer.
New systemic regimens are being integrated into the treatment paradigm for resectable non–small cell lung cancer in the neoadjuvant and adjuvant settings, expanding options for patients with earlier-stage disease who face a challenging prognosis.
Naomi Dempsey, MD, discusses the role of de-escalation therapy in early-stage, HER2-positive breast cancer and provides highlights from ongoing clinical trials in the space.
Each May during Oncology Nursing Month, Florida Cancer Specialists & Research Institute, LLC recognizes two outstanding nurses within the practice.
Heather McArthur, MD, MPH, described how the data from DESTINY-Breast03 reshapes the treatment landscape and offers added benefit to patients with brain metastases.
Kelsey Klute, MD, discusses the importance of frontline checkpoint inhibitors in advanced gastric cancer, the need for predictive biomarkers in hepatocellular carcinoma, and research investigating immunotherapy in HER2-negative gastric and esophagus cancer and esophagus and gastroesophageal junction cancer.
To date, oncologists have not seen much success with immunotherapy for neuroendocrine tumors.
Nurix Therapeutics has initiated an ongoing phase 1 trial to examine NX-2127, an immunomodulatory oral BTK inhibitor, in patients with chronic lymphocytic leukemia.
Galinpepimut-S in combination with the PD-1 inhibitor pembrolizumab elicited a clinical benefit in patients with Wilms’ tumor-1-positive relapsed/refractory platinum-resistant advanced metastatic ovarian cancer, according to top line-line data from a phase 1/2 trial (NCT03761914).
Press Release
The Canopy Cancer Collective, a national nonprofit organization that strives to fuel better treatments and outcomes for pancreatic cancer patients, has awarded The Tisch Cancer Institute at Mount Sinai a $500,000 grant to support continued innovation in its multidisciplinary treatment of pancreatic cancer.
The FDA has approved the biologics license application for pegfilgrastim-pbbk, a biosimilar referencing Neulasta for the treatment of neutropenia.
Ishwaria M. Subbiah, MD, MS, brings attention to the perpetrators of sexual harassment, outlines the nuances of how these experiences affect personal wellbeing and job satisfaction, and highlights the need for accountability as a first step toward systemic change across the oncology community.
There are serious concerns about textbook descriptions of peer review, specifically within the realm of clinical research, which pose a threat to both the objectivity of the field of investigative medicine and, perhaps most importantly, to the public’s support of clinical science.
Novel agents seek to improve and expand the efficacy of the current standard of care for patients with acute graft-vs-host disease, specifically those with high-risk disease.
The addition of sorafenib to conventional chemotherapy was safe and demonstrated evidence of improved outcomes in pediatric patients with FLT3-ITD–positive acute myeloid leukemia.
Although lower fatality rates were reported during the omicron wave of the COVID-19 pandemic in patients with chronic lymphocytic leukemia, close monitoring and preemptive antiviral therapy is still recommended following a positive SARS-CoV-2 test, particularly in patients with close hospital contacts and those older than 70 years of age with at least one comorbidity.
Neoadjuvant administration of the antibody drug conjugate enfortumab vedotin-ejfv represents a potential future treatment option for patients with muscle invasive bladder cancer who are ineligible for cisplatin-based chemotherapy.
The FDA has granted accelerated approval to tisagenlecleucel for the treatment of adult patients with relapsed or refractory follicular lymphoma following 2 or more lines of systemic therapy.
The FDA has approved nivolumab in combination with fluoropyrimidine- and platinum-containing chemotherapy and nivolumab plus ipilimumab as a first-line treatment for adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma, irrespective of PD-L1 status.
Uliledlimab in combination with toripalimab generated notable response rates in patients with advanced non–small cell lung cancer who were previously ineligible to receive standard-of-care treatment.
